NCT01999413View on ClinicalTrials.gov

Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2018

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

OMEGAVEN

AML Study treatment induction phase

DRUG

Daunorubicin

AML Study treatment induction phase

DRUG

Cytarabine

AML Study treatment induction phase

Trial Locations (1)

37044

Emmanuel GYAN, Tours

Sponsors

Collaborators (1)

Fresenius Kabi
All Listed Sponsors
collaborator

Fresenius Kabi

INDUSTRY

lead

French Innovative Leukemia Organisation

OTHER